[article] 
inJournal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355

Titre :	Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur
Année de publication :	2022
Article en page(s) :	p.5342-5355
Langues :	Anglais (eng)
Mots-clés :	Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication.
Index. décimale :	PER Périodiques
Résumé :	This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.
En ligne :	http://dx.doi.org/10.1007/s10803-021-05396-9
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489

[article] Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur . - 2022 . - p.5342-5355.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355

Mots-clés :	Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication.
Index. décimale :	PER Périodiques
Résumé :	This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.
En ligne :	http://dx.doi.org/10.1007/s10803-021-05396-9
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489